Machine learning-based prediction of surgical benefit in borderline resectable and locally advanced pancreatic cancer

被引:0
|
作者
Zhang, Leiming [1 ,2 ]
Yu, Zehao [2 ]
Jin, Rong [1 ,2 ]
Yang, Xuanang [2 ]
Ying, Dongjian [1 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Dept Minimally Invas Surg, Ningbo, Zhejiang, Peoples R China
[2] Ningbo Univ, Hlth Sci Ctr, Ningbo, Zhejiang, Peoples R China
关键词
Machine learning; Borderline resectable pancreatic cancer; Locally advanced pancreatic cancer; Postoperative; Model prediction; DUCTAL ADENOCARCINOMA; SURGERY; 5-FLUOROURACIL; CHEMOTHERAPY; FOLFIRINOX; CONSENSUS; THERAPY;
D O I
10.1007/s00432-023-05071-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionSurgery represents a primary therapeutic approach for borderline resectable and locally advanced pancreatic cancer (BR/LAPC). However, BR/LAPC lesions exhibit high heterogeneity and not all BR/LAPC patients who undergo surgery can derive beneficial outcomes. The present study aims to employ machine learning (ML) algorithms to identify those who would obtain benefits from the primary tumor surgery.MethodsWe retrieved clinical data of patients with BR/LAPC from the Surveillance, Epidemiology, and End Results (SEER) database and classified them into surgery and non-surgery groups based on primary tumor surgery status. To eliminate confounding factors, propensity score matching (PSM) was employed. We hypothesized that patients who underwent surgery and had a longer median cancer-specific survival (CSS) than those who did not undergo surgery would certainly benefit from surgical intervention. Clinical and pathological features were utilized to construct six ML models, and model effectiveness was compared through measures such as the area under curve (AUC), calibration plots, and decision curve analysis (DCA). We selected the best-performing algorithm (i.e., XGBoost) to predict postoperative benefits. The SHapley Additive exPlanations (SHAP) approach was used to interpret the XGBoost model. Additionally, data from 53 Chinese patients prospectively collected was used for external validation of the model.ResultsAccording to the results of the tenfold cross-validation in the training cohort, the XGBoost model yielded the best performance (AUC = 0.823, 95%CI 0.707-0.938). The internal (74.3% accuracy) and external (84.3% accuracy) validation demonstrated the generalizability of the model. The SHAP analysis provided explanations independent of the model, highlighting important factors related to postoperative survival benefits in BR/LAPC, with age, chemotherapy, and radiation therapy being the top three important factors.ConclusionBy integrating of ML algorithms and clinical data, we have established a highly efficient model to facilitate clinical decision-making and assist clinicians in selecting the population that would benefit from surgery.
引用
收藏
页码:11857 / 11871
页数:15
相关论文
共 50 条
  • [11] The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition
    Soweid, Assaad M.
    ENDOSCOPIC ULTRASOUND, 2017, 6 : S76 - S78
  • [12] FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
    Yoo, Changhoon
    Hwang, Inhwan
    Song, Tae Jun
    Lee, Sang Soo
    Jeong, Jae Ho
    Park, Do Hyun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Byun, Jae Ho
    Park, Jin-hong
    Hwang, Dae Wook
    Song, Ki Byung
    Lee, Jae Hoon
    Lee, Woohyung
    Chang, Heung-Moon
    Kim, Kyu-pyo
    Kim, Song Cheol
    Ryoo, Baek-Yeol
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [13] Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
    Jeon, Hyun Jeong
    Lim, Soo Yeun
    Jeong, Hyejeong
    Yoon, So Jeong
    Kim, Hongbeom
    Shin, Sang Hyun
    Heo, Jin Seok
    Han, In Woong
    BIOMEDICINES, 2023, 11 (08)
  • [14] Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
    de Carvalho, Luis Filipe Abreu
    Gryspeerdt, Filip
    Rashidian, Niki
    Van Hove, Kobe
    Maertens, Lambertine
    Ribeiro, Suzane
    Hoorens, Anne
    Berrevoet, Frederik
    BMC SURGERY, 2023, 23 (01)
  • [15] Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?
    Daniel M. Halperin
    Gauri R. Varadhachary
    Current Oncology Reports, 2014, 16
  • [16] Borderline Resectable and Locally Advanced Pancreatic Cancers A Review of Definitions, Diagnostics, Strategies for Treatment, and Future Directions
    Khachfe, Hussein H.
    Habib, Joseph R.
    Nassour, Ibrahim
    Al Harthi, Salem
    Jamali, Faek R.
    PANCREAS, 2021, 50 (09) : 1243 - 1249
  • [17] Surgical exploration with non-resection in the setting of resectable, borderline and locally advanced pancreatic cancer
    Soreide, Kjetil
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022, 21 (03) : 205 - 206
  • [18] Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection
    Ren, Weizheng
    Xourafas, Dimitrios
    Ashley, Stanley W.
    Clancy, Thomas E.
    AMERICAN SURGEON, 2022, 88 (12) : 2899 - 2906
  • [19] Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery?
    Bratlie, Svein Olav
    Wennerblom, Johanna
    Vilhav, Caroline
    Persson, Jan
    Rangelova, Elena
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (05) : 2450 - 2460
  • [20] Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer
    Kang, Ji Hun
    Lee, Seung Soo
    Kim, Jin Hee
    Byun, Jae Ho
    Kim, Hyoung Jung
    Yoo, Changhoon
    Kim, Kyu-pyo
    Ryoo, Baek-Yeol
    Kim, Song Cheol
    EUROPEAN RADIOLOGY, 2021, 31 (02) : 864 - 874